OpenEvidence Raises $210 Million at $3.5 Billion Valuation to Expand AI Tools for Physicians

OpenEvidence, the leading AI-powered medical search platform used by verified U.S. clinicians, has closed a $210 million Series B financing round at a valuation of $3.5 billion. The round was co‑led by Google Ventures and Kleiner Perkins, with participation from Sequoia (which led its earlier Series A), Coatue, Conviction, Greycroft, and Thrive. This brings total funding since its founding to over $300 million.

Launched in 2022 by serial entrepreneur Daniel Nadler (also founder of Kensho), OpenEvidence serves more than 40% of U.S. physicians, with more than 10,000 hospitals and medical centers using the platform daily. Monthly physician consultations have surged from 358,000 in July 2024 to over 8.5 million in July 2025—a more than 2,000% year-over-year growth. The company onboarded 65,000 new verified U.S. clinicians in the past month alone, and expects over 100 million Americans this year will be treated by a doctor using OpenEvidence.

Physicians face an unprecedented deluge of medical research, with the volume doubling every five years. Traditional literature tools are slow and fragmented. OpenEvidence addresses this by integrating strategic content partnerships—including the AMA, NEJM, JAMA and its 11 specialty journals—to provide clinicians with curated, up-to-date insights in seconds. Physicians can enter a clinical question or patient case detail and receive a referenced, evidence-based answer instantly, streamlining the process and improving patient outcomes.

Alongside its fast search engine—delivering answers in just 5–10 seconds—OpenEvidence has launched DeepConsult™, the first AI agent purpose-built for physicians. DeepConsult autonomously analyzes hundreds of peer-reviewed studies in parallel, producing PhD-level integrative research reports in hours rather than months. Although it consumes over 100 times the compute and cost of standard searches, DeepConsult is offered free to verified U.S. clinicians as part of OpenEvidence’s mission to democratize access at the point of care.

Founder Daniel Nadler emphasized the platform’s role in addressing clinician burnout and a projected shortage of nearly 100,000 U.S. physicians by 2030: “When physicians’ lives are hard, patients’ lives are harder.” Investors like Google Ventures and Kleiner Perkins praised Nadler as a rare talent who is building one of the fastest-growing applications in tech history. They cited OpenEvidence’s widespread adoption—used daily by 40% of U.S. doctors—as proof of its trust and impact.

With the new capital, OpenEvidence plans to expand content partnerships and enhance its medical knowledge library further. CEO and co‑founder Nadler, previously the founder of Kensho (acquired for $700 million in 2018), was named in the TIME100 Health list in 2025, underscoring the global health impact of his work.

OpenEvidence has rapidly become a mission-critical tool for modern clinical practice—transforming the way doctors access, evaluate, and apply evidence-based knowledge at the point of care.